Mucosal Healing Biomarker Profiling for Anti-TNF Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing mucosal healing in inflammatory bowel diseases like Crohn's disease and ulcerative colitis are invasive and do not effectively measure the underlying cause of disease activity, leading to challenges in optimizing therapy and monitoring efficacy.
Innovation Solution
A non-invasive method for measuring mucosal healing markers, including a panel of biomarkers such as AREG, EREG, HB-EGF, and VEGF, to generate a mucosal healing index through statistical analysis, allowing for personalized therapeutic management and optimization of anti-TNF therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If endoscopy is used to assess mucosal healing, then measurement precision is improved, but ease of operation deteriorates due to invasive procedure requirements
Solution Approach 1:
The patent replaces the mechanical endoscopic procedure with a non-invasive biochemical assay system. Instead of physically inserting an endoscope into the patient's gastrointestinal tract, the invention uses blood-based biomarker measurements (including growth factors, cytokines, and other molecular markers) to assess mucosal healing status, thereby eliminating procedural discomfort while maintaining diagnostic capability
Solution Approach 2:
The patent introduces biomarkers as intermediary substances that indirectly reflect mucosal healing status. Rather than directly visualizing the mucosa through endoscopy, the invention measures blood-based intermediary markers (such as growth factors and inflammatory mediators) that correlate with mucosal healing, providing a non-invasive proxy measurement
2Ease of operation
If current disease activity indices are used, then ease of operation is improved, but measurement precision deteriorates because they fail to measure underlying inflammation or resolution
Solution Approach 1:
The patent fundamentally changes the measurement parameters from clinical symptom-based indices to molecular biomarker concentrations. Instead of relying on patient-reported symptoms and physical exam findings, the invention measures specific biochemical parameters (growth factors, cytokines, inflammatory markers) in blood samples, thereby capturing the underlying pathological processes that traditional indices miss
Solution Approach 2:
The patent creates a biochemical copy or surrogate representation of mucosal healing status through blood-based biomarker profiles. Rather than directly measuring mucosal tissue properties, the invention uses circulating molecular markers that replicate or reflect the state of mucosal healing, providing an indirect but accurate assessment
3Measurement precision
If frequent endoscopies are performed to monitor mucosal healing, then measurement precision is improved, but loss of time and increased cost worsen
Solution Approach 1:
The patent replaces the time-intensive endoscopic monitoring system with a rapid biochemical testing system. Blood samples can be drawn quickly in outpatient settings and analyzed using automated assays, dramatically reducing the time required for monitoring compared to scheduling and performing repeated endoscopic procedures
Data Source
AI summary
The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and/or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.